{"schema_version":"secwatch.filing_event.v1","accession":"0001601830-24-000018","form_type":"8-K","ticker":"RXRX","cik":"0001601830","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.771675+00:00","generated_at":"2026-06-05T11:56:08.928729+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Recursion reports Q4 net loss of $93M, cash $391.6M; '24 clinical data readouts planned","bullets":["Net loss $93M in Q4 2023 vs $57.5M a year ago; full-year loss $328.1M vs $239.5M.","Cash and equivalents $391.6M at Dec 31, 2023, down from $549.9M a year earlier.","R&D expenses rose to $69.5M in Q4 from $44M; operating cash burn $287.8M for 2023.","Key clinical milestones: REC-994 Phase 2 data Q3 2024; REC-2282 data Q4 2024; REC-3964 Phase 2 start in 2024.","Named Kristen Rushton as Chief Business Operations Officer; in-licenced Bayer fibrosis program (Target Epsilon) entering IND-enabling."],"urls":{"canonical":"https://secwatch.observer/filing/0001601830-24-000018","json":"https://secwatch.observer/filing/0001601830-24-000018.json","markdown":"https://secwatch.observer/filing/0001601830-24-000018.md","text":"https://secwatch.observer/filing/0001601830-24-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000018/0001601830-24-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000018/rxrx-20240227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T11:56:08.928729+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2e2a1d35fe362d8b993005258fadc3e7f4a8104e","claim":"RECURSION PHARMACEUTICALS, INC. reported financial results for the fourth quarter and fiscal year ended December 31, 2023.","evidence_excerpt":"issued a press release announcing its results of operations and financial condition for the fourth quarter and fiscal year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000018/0001601830-24-000018-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}